JP7414530B2 - 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 - Google Patents

細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 Download PDF

Info

Publication number
JP7414530B2
JP7414530B2 JP2019572319A JP2019572319A JP7414530B2 JP 7414530 B2 JP7414530 B2 JP 7414530B2 JP 2019572319 A JP2019572319 A JP 2019572319A JP 2019572319 A JP2019572319 A JP 2019572319A JP 7414530 B2 JP7414530 B2 JP 7414530B2
Authority
JP
Japan
Prior art keywords
cells
cell
neural progenitor
medium
differentiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019572319A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019160148A5 (https=
JPWO2019160148A1 (ja
Inventor
賢司 吉田
学 吉川
明香 関谷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Sumitomo Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd, Sumitomo Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of JPWO2019160148A1 publication Critical patent/JPWO2019160148A1/ja
Publication of JPWO2019160148A5 publication Critical patent/JPWO2019160148A5/ja
Priority to JP2023166389A priority Critical patent/JP7797028B2/ja
Application granted granted Critical
Publication of JP7414530B2 publication Critical patent/JP7414530B2/ja
Priority to JP2025259834A priority patent/JP2026042046A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0068—General culture methods using substrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/32—Materials or treatment for tissue regeneration for nerve reconstruction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
JP2019572319A 2018-02-19 2019-02-18 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法 Active JP7414530B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023166389A JP7797028B2 (ja) 2018-02-19 2023-09-27 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
JP2025259834A JP2026042046A (ja) 2018-02-19 2025-12-17 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018027455 2018-02-19
JP2018027455 2018-02-19
PCT/JP2019/005914 WO2019160148A1 (ja) 2018-02-19 2019-02-18 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023166389A Division JP7797028B2 (ja) 2018-02-19 2023-09-27 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法

Publications (3)

Publication Number Publication Date
JPWO2019160148A1 JPWO2019160148A1 (ja) 2021-02-04
JPWO2019160148A5 JPWO2019160148A5 (https=) 2022-02-16
JP7414530B2 true JP7414530B2 (ja) 2024-01-16

Family

ID=67618694

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019572319A Active JP7414530B2 (ja) 2018-02-19 2019-02-18 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
JP2023166389A Active JP7797028B2 (ja) 2018-02-19 2023-09-27 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
JP2025259834A Pending JP2026042046A (ja) 2018-02-19 2025-12-17 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023166389A Active JP7797028B2 (ja) 2018-02-19 2023-09-27 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
JP2025259834A Pending JP2026042046A (ja) 2018-02-19 2025-12-17 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法

Country Status (7)

Country Link
US (1) US20200405768A1 (https=)
EP (1) EP3757208A4 (https=)
JP (3) JP7414530B2 (https=)
CN (1) CN111788303B (https=)
CA (1) CA3096870A1 (https=)
TW (1) TW202000902A (https=)
WO (1) WO2019160148A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020387259A1 (en) * 2019-11-20 2022-06-09 Kyoto University Method for freezing neural cells
WO2021100830A1 (ja) * 2019-11-20 2021-05-27 大日本住友製薬株式会社 細胞凝集体の凍結方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034012A1 (ja) 2013-09-05 2015-03-12 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞の誘導方法
US20150265652A1 (en) 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CA2277278A1 (en) 1997-01-10 1998-07-16 Life Technologies, Inc. Embryonic stem cell serum replacement
US6280718B1 (en) 1999-11-08 2001-08-28 Wisconsin Alumni Reasearch Foundation Hematopoietic differentiation of human pluripotent embryonic stem cells
UY27224A1 (es) 2001-03-23 2002-10-31 Bayer Corp Inhibidores de la rho-quinasa
PE20020958A1 (es) 2001-03-23 2002-11-14 Bayer Corp Inhibidores de la rho-quinasa
WO2002101057A1 (fr) 2001-06-08 2002-12-19 Dnavec Research Inc. Transfert genique dans des cellules souches embryonnaires de primate a l'aide d'un virus de l'immunodeficience simienne de pseudo type vsv-g utilise comme vecteur
JP4505228B2 (ja) 2002-01-10 2010-07-21 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト Ｒｈｏ−キナーゼ阻害剤
MXPA04007196A (es) 2002-01-23 2005-06-08 Bayer Pharmaceuticals Corp Inhibidores de rho-quinasa.
EP1470121B1 (en) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidine derivatives as rho-kinase inhibitors
ES2273047T3 (es) 2002-10-28 2007-05-01 Bayer Healthcare Ag Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa.
JP4573332B2 (ja) 2003-01-24 2010-11-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ｌｒｐ４／Ｃｏｒｉｎドーパミン産生ニューロン増殖前駆細胞マーカー
US20050289257A1 (en) 2004-06-24 2005-12-29 Fink Thomas M Self-powered USB device with USB power line reset and related USB host and USB system
JP2009050194A (ja) * 2007-08-27 2009-03-12 Sumitomo Bakelite Co Ltd 細胞凝集塊形成培養用容器
US20100087486A1 (en) 2008-05-30 2010-04-08 Hiroshi Nakamura Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
JP5590646B2 (ja) 2009-10-08 2014-09-17 国立大学法人大阪大学 ヒト多能性幹細胞用培養基材およびその利用
JP6090937B2 (ja) 2011-07-27 2017-03-08 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞マーカー
CA2912345C (en) * 2013-05-16 2020-10-06 Sumitomo Dainippon Pharma Co., Ltd. Transplantation adjuvant in cell therapy using neural progenitor cells
US9619881B2 (en) * 2013-09-26 2017-04-11 Cellogy, Inc. Method and system for characterizing cell populations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034012A1 (ja) 2013-09-05 2015-03-12 国立大学法人京都大学 新規ドーパミン産生神経前駆細胞の誘導方法
US20150265652A1 (en) 2014-03-21 2015-09-24 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2017183736A1 (ja) 2016-04-22 2017-10-26 国立大学法人京都大学 ドーパミン産生神経前駆細胞の製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
米サイトノーム社と独占的商品販売代理店契約を締結，IK INABATA 「最新情報」（ニュースリリース），[検索日 2019.04.24]，稲畑産業株式会社 [オンライン]，2017年09月06日，https://www.inabata.co.jp/news/entry-56.html

Also Published As

Publication number Publication date
TW202000902A (zh) 2020-01-01
WO2019160148A1 (ja) 2019-08-22
JP2023169391A (ja) 2023-11-29
JPWO2019160148A1 (ja) 2021-02-04
JP7797028B2 (ja) 2026-01-13
EP3757208A4 (en) 2021-12-01
EP3757208A1 (en) 2020-12-30
CN111788303B (zh) 2024-11-05
CN111788303A (zh) 2020-10-16
JP2026042046A (ja) 2026-03-10
US20200405768A1 (en) 2020-12-31
CA3096870A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
JP7397448B2 (ja) 神経組織の製造方法
JP7356658B2 (ja) ドーパミン産生神経前駆細胞の製造方法
JP7742999B2 (ja) 網膜組織の製造方法
US20180298330A1 (en) Means and methods for generating midbrain organoids
JP7793137B2 (ja) 背側化シグナル伝達物質又は腹側化シグナル伝達物質による錐体視細胞又は桿体視細胞の増加方法
JP7465569B2 (ja) ヒト多能性幹細胞から視床下部ニューロンへの分化誘導
WO2018164240A1 (ja) 網膜色素上皮細胞の製造方法
JP2026042046A (ja) 細胞凝集体、細胞凝集体の混合物及びそれらの製造方法
HK40039979A (en) Cell aggregate, mixture of cell aggregates, and method for preparing same
HK40029697A (en) Method for amplifying cone photoreceptors or rod photoreceptors using dorsalization signal transmitter or ventralization signal transmitter

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200701

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220207

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220207

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230308

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230518

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230627

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20230815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231003

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231212

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231228

R150 Certificate of patent or registration of utility model

Ref document number: 7414530

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350